Clinical Trial Detail

NCT ID NCT03471260
Title Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

myeloproliferative neoplasm

Therapies

Azacitidine + Ivosidenib + Venetoclax

Ivosidenib + Venetoclax

Age Groups: adult senior

Additional content available in CKB BOOST